chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Chickenpox; sick; Shortness of breath; Fever over 102; Hives; Swollen lymph nodes at the back of neck upto head; Fever; Headache; Bad rash all over the body; Blisters; Diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of VARICELLA (Chickenpox) and ILLNESS (sick) in a 32-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (Historical condition not reported.).    On 09-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Apr-2021, the patient experienced PYREXIA (Fever), HEADACHE (Headache), RASH (Bad rash all over the body), BLISTER (Blisters), DIARRHOEA (Diarrhea), PYREXIA (Fever over 102), URTICARIA (Hives) and LYMPHADENOPATHY (Swollen lymph nodes at the back of neck upto head). On 13-Apr-2021, the patient experienced DYSPNOEA (Shortness of breath). On an unknown date, the patient experienced VARICELLA (Chickenpox) (seriousness criterion hospitalization) and ILLNESS (sick) (seriousness criterion hospitalization). At the time of the report, VARICELLA (Chickenpox), ILLNESS (sick), PYREXIA (Fever), HEADACHE (Headache), RASH (Bad rash all over the body), BLISTER (Blisters), DIARRHOEA (Diarrhea), DYSPNOEA (Shortness of breath), PYREXIA (Fever over 102), URTICARIA (Hives) and LYMPHADENOPATHY (Swollen lymph nodes at the back of neck upto head) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood culture: unknown (Inconclusive) unknown. On an unknown date, Computerised tomogram head: unkown (Inconclusive) unknown. On an unknown date, Lumbar puncture: unknown (Inconclusive) unknown.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       On 16 Apr 2021: follow up information included consumer being transported to the emergency room (ER).  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded   This case was linked to MOD21-075845 (E2B Linked Report).   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 13-Apr-2021: No specific follow-up information recorded. On 14-Apr-2021: Event - Blisters added. On 16-Apr-2021: No specific follow-up information recorded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded MOD21-075845:FU
developed diffuse erythematous macular rash to trunk and upper extremities; mild facial swelling; tachycardic; fever/febrile; headache; myalgias; fatigue; This is a spontaneous report from a contactable other healthcare professional. A 17-year-old non-pregnant female patient received second dose of BNT162B2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot Number: EW0172, Expiration date was not reported), via an unspecified route of administration on 30May2021 as dose 2, single (at the age of 17-year-old) for COVID-19 immunization. Patient had no medical history and no known drug allergy (NKDA). Historical vaccine included patient received first dose of BNT162B2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot Number: EW0172, Expiration date was not reported), via an unspecified route of administration on 09May2021 as dose 1, single (at the age of 17-year-old) for COVID-19 immunization. The patient's concomitant medications were not reported. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient was not diagnosed with COVID-19, prior to vaccination. Since the vaccination, patient had not been tested for COVID-19. On 30May2021, since the day of vaccine administration, patient had fever, headache, myalgias and fatigue. On 02Jun2021, 3rd day post vaccine, patient developed diffuse erythematous macular rash to trunk and upper extremities, had mild facial swelling and negative for angioedema, was tachycardic and febrile on exam. Patient had Doctor or other healthcare professional office/clinic visit for all the events. Therapeutic measures were taken as a result of developed diffuse erythematous macular rash to trunk and upper extremities, mild facial swelling, tachycardic, fever, headache, myalgias and fatigue and treatment included steroids and antihistamines for all the events. The outcome of all the events was not recovered.   Follow-up attempts are completed. No further information is expected.
Redness, Hot to the Touch, Itching, Swelling, Hard Lump/Knot - symptoms continue at 10+days
Information has been received from a pharmacist via a company representative referring to a 61 years old female patient. The patient's pertinent medical history and drug reactions/allergies were unknown. On 22-JUN-2016, the patient was vaccinated with ZOSTAVAX (lot # and expiry date were not reported, 1 shot), subcutaneously for prevention of shingles. Concomitant therapies were unknown. The next day, on 23-JUN-2016, the patient experienced a slight fever, and a reddish mark smaller than palm size around the injection site. On the same day, the patient returned to the pharmacy and reported the events. The patient went to her physician and he stated that it was nothing serious. No treatment was given for the adverse events. The mark went away the next day (24-JUN-2016) and the patient had recovered from slight fever on an unspecified date in 2016. The causality between the events and ZOSTAVAX was not reported. Additional information has been requested.
Adverse event: PT received second dose of Pfizer on cot laying supine r/t anticipated vaso-vagal reaction. PT sat on edge of cot 5 minutes post vaccination. Daughter translated for PT, who reported she was "feeling fine". Daughter assisted PT to stand and then back to a seated position, then to lay on cot. PT became unresponsive, breathing was normal, pulses were present. EMTs were called at 1525, arriving at 1526 and assessed PT. PT had  improved enough at 1540 to c/o feeling "dizzy, room spinning". Daughter reported that PT "does this a few times a month." and reported that PT had recently been evaluated by neurologists and cardiologists with no abnormality found. EMTs assisted PT to sit up on cot, but PT was unable to tolerate sitting for more than 1 minute and was assisted to lay supine again. EMTs called for transport to Hospital. PT remained lethargic, with eyes open, and responding to daughter. Treatment: EMTs were called at 1525 and arrived at 1526, assessed PT. VS at 1525: 158/78 BP, HR 86, RR 16, SPO2 100%, BS 316. VS at 1533: BP 156/76, HR 77, RR 20, SPO2 100%.  Outcome: Transferred to Medical Center, accompanied by daughter Responding HCP: EMTs on site, RN
my body just keeps getting weaker and weaker; It's like I have no immune system anymore; couldn't get out of bed; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID:. The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2), in Aug2021 as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, I received the first round of your double Covid vaccine back in Jan2021), administration date: Jan2021, for COVID-19 immunization, reaction(s): "I had a reaction to it in my left arm & that night my right hand started trembling", "I had a reaction to it in my left arm & that night my right hand started trembling"; Bnt162b2 (DOSE 2, SINGLE, I received the first round of your double Covid vaccine back in Jan2021, Anatomical location: right arm), administration date: Jan2021, for COVID-19 immunization. The following information was reported: MOVEMENT DISORDER (non-serious) with onset Aug2021, outcome "unknown", described as "couldn't get out of bed"; ASTHENIA (non-serious), outcome "unknown", described as "my body just keeps getting weaker and weaker"; DECREASED IMMUNE RESPONSIVENESS (non-serious), outcome "unknown", described as "It's like I have no immune system anymore". Additional information: In August I had the Delta variant couldn't get out of bed, 2022 covid, 2023 covid. It's like I have no immune system anymore thanks to your vaccine and my body just keeps getting weaker and weaker. Doctors are no help. Long Covid is killing me.  The information on the batch/lot number for bnt162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-PV202300167477 Same patient and reporter; different vaccine dose and event;US-PFIZER INC-202300321704 Same patient and reporter; different vaccine dose and event;
This spontaneous report as received from a nurse refers to an unknown number of patients of unknown age and gender. Since 08-JAN-2015 the patients were vaccinated with VARIVAX (Merck) (administered subcutaneously, dose and indication were not reported) which underwent supported defrost cycling. No adverse effects reported. Additional information has been requested.
2 days later I developed pain in my chest, back, lats, and entire arm. I have sharp numbing pain periodically from my armpit to my pinky finger. This pain has only grown worse since onset despite my doctor prescribing oral steroids and pain meds. Painful to sneeze, cough and laugh
Next day (Saturday, 1/23/21) I experienced extreme myalgia and lethargy, sweats, chills, itching and rash around neck area, stiffness in left shoulder and neck.  (Injection was in the left arm).  Rash & itching continued through Sunday, 1/24/21 & Monday, 1/25/21 but seems to be subsiding.
raised and hard; continued to have hives at the site of injection; It was very swollen; This spontaneous case was reported by a consumer and describes the occurrence of DISCOMFORT (raised and hard), INJECTION SITE URTICARIA (continued to have hives at the site of injection) and INJECTION SITE SWELLING (It was very swollen) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 0104217) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced DISCOMFORT (raised and hard), INJECTION SITE URTICARIA (continued to have hives at the site of injection) and INJECTION SITE SWELLING (It was very swollen). At the time of the report, DISCOMFORT (raised and hard), INJECTION SITE URTICARIA (continued to have hives at the site of injection) and INJECTION SITE SWELLING (It was very swollen) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant and treatment medications were provided
pt recvd vax & exp fatigue, muscle pain followed by arthralgia & nodules on the fingers joints; lab tests revealed elevated sedimentation rate;
Acute pancreatitis - epigastric pain, elevated lipase. Patient also has gallstones noted in gallbladder but without biliary dilatation or elevation in bilirubin or alk phos to suggest CBD obstruction. Gallstone pancreatitis seems most likely, but cannot exclude a vaccine related event especially with onset of symptoms the day after vaccination. Patient was admitted to hospital and noted complete resolution of pain with supportive measures within the first 24 hours.
immediately felt dizzy, heart racing, brain fog... upon getting home began vomiting and was very nauseous and dizzy... this morning can barely lift arm
Immediately following the vaccine, my son felt totally fine. The pharmacist told us to walk around the store for 15 minutes. 8 minutes after the vaccine, my son said his arm felt tingly. He immediately began sweating profusely and said that he felt dizzy. I made him sit down and he then said that he felt nauseous. Within 5 minutes of the onset of symptoms, he vomited. He was pale and his forehead was cold/clammy. The pharmacist said it was anxiety and nothing to be concerned about. However, my son said that he did not feel worried, anxious, etc. prior to or immediately following the vaccine.
- Pt complains of severe joint/muscle pain all over body. Says can not get out of bed.
Pt was given the immunizations and he tolerated them well. On 05/23/2002, one day post-vaccination, pt's mother noted firm, erythematous area of 9cm x 10cm at right deltoid. Pt was seen in the office on 05/24/2002 at 9am.
reduced immunity by 30% towards other viruses.; Initial information was received on 03-Oct-2020 regarding an unsolicited valid non-serious case from a consumer/non-health care professional via social media.  This case involves a patient of (unknown demographics) who was experienced reduced immunity by 30% towards other viruses (decreased immune responsiveness), after receiving vaccine INFLUENZA VACCINE.  The patient's medical history, past medical treatment(s), concomitant therapy, vaccination(s) and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via an unknown route at an unknown administration site.  On an unknown date, the patient developed a non-serious reduced immunity by 30% towards other viruses (decreased immune responsiveness) (unknown latency) following the administration of INFLUENZA VACCINE.  There were no laboratory data/results available.  It was not reported if the patient received a corrective treatment for the event.  At time of reporting, outcome of the event was unknown.  There will be no information available on batch number for this case.
He had flu-like symptoms from the Shingrix vaccine; This case was reported by a pharmacist via other manufacturer and described the occurrence of influenza-like symptoms in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 14th May 2021, the patient received Shingrix. On 14th May 2021, less than a day after receiving Shingrix, the patient experienced influenza-like symptoms. On an unknown date, the outcome of the influenza-like symptoms was unknown.   The reporter considered the influenza-like symptoms to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The patient experienced flu like symptoms from Shingrix vaccine. The pharmacist reported that they had opened and diluted the vaccine at the pharmacy and when they received the vaccine, it was sealed and intact. The reporter consented to follow up. No further information was reported.
Diffuse muscle pain and tenderness, fatigue, hypersomnia, altered mental status, hallucinations.
Treatment of COVID-19; Treatment of COVID-19; Name of Drug as Reported: Pfizer / BioNTech; Patient Drug Start date: 20Sep2022; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 69-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 20Sep2022 as dose 5 (booster), single (Lot number: GH9730), in left arm and on 01May2023 at 13:00 as dose 6 (booster), single (Lot number: GK1337) at the age of 68 years, in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 18Jan2021 as dose 1, single (Lot number: 042l20A), in left arm, on 13Feb2021 as dose 2, single (Lot number: 024m20a), in left arm, on 22Oct2021 as dose 3 (booster), single (Batch/Lot number: unknown), in left arm and on 18Apr2022 as dose 4 (booster), single (Lot number: 0021m21a), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Small bowel obstruction", start date: 2021 (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 20Sep2022, outcome "unknown", described as "Name of Drug as Reported: Pfizer / BioNTech; Patient Drug Start date: 20Sep2022"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 17Aug2023, outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (17Aug2023) Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19 including Paxlovid from 17Aug2023 to 21Aug2023.
This spontaneous report as received from a physician and a medical assistant via a company representative refers to a 15 year old female patient. The patient's concurrent conditions included amoxicillin allergy (it gave her hives on an unknown date) and allergy to SEPTRA. None concomitant medications were reported. The physician stated that the patient had no history of migraines, nor was there a family history of migraines. On 18-MAR-2016 at 11:15, the patient was vaccinated with the first dose of GARDASIL 9 (lot # L045711, expiration date 08-MAY-2017; dose and route was not reported). The physician stated that the patient remained in the office for 20 minute post vaccination without any effects. The physician stated per the patient's mother who reported to the office at an unspecified time that when patient was driving home, about 30 to 35 minutes post vaccination (approximately on 18-MAR-2016 at 11:45) the patient started to experience a sharp head pain on right side and blurry vision. The physician stated per the mother that the headache and blurry vision persisted so upon further communication between the patient's mother and the physician, the physician advised parents to take the patient to the hospital's emergency room (the patient was seen in the emergency room approximately 12 hours post vaccination). The physician stated that the emergency room staff did not find anything except blurred vision. The physician also stated that the patient continued with blurred vision in right eye and was later assessed by an unspecified eye specialist that confirmed that blurred vision but also did not find anything else. The patient was not hospitalized and no treatment was given for the adverse events. The outcome of the adverse events was reported as recovered in 2016. It was also reported that the patient was doing fine now. The relatedness between the adverse events and GARDASIL 9 was not reported. Additional information has been requested.
4 hours after second dose of Maderna vaccine developed unilateral right eye pain, severe headache and scalp irritation.
Woke up on the 24th with a puffiness in the face, patient looked at  the back of her throat and noticed some swelling, pt was able to maintain the airway.   Pt was able to stay monitor sx which resolved the next day.
stomach pain; jaw pain; ear pain; "knocked out from tiredness"; tiredness; This spontaneous case was reported by a consumer and describes the occurrence of ABDOMINAL PAIN UPPER (stomach pain), PAIN IN JAW (jaw pain), EAR PAIN (ear pain), FATIGUE ("knocked out from tiredness") and FATIGUE (tiredness) in a 64-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 018B21A and 006B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included OXYCODONE, FUCOIDAN and LISINOPRIL for an unknown indication.   On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ABDOMINAL PAIN UPPER (stomach pain), PAIN IN JAW (jaw pain), EAR PAIN (ear pain), FATIGUE ("knocked out from tiredness") and FATIGUE (tiredness). The patient was treated with BISMUTH SUBSALICYLATE (PEPTO BISMOL [BISMUTH SUBSALICYLATE]) for Adverse event, at an unspecified dose and frequency and CALCIUM CARBONATE (TUMS [CALCIUM CARBONATE]) at an unspecified dose and frequency. At the time of the report, ABDOMINAL PAIN UPPER (stomach pain), PAIN IN JAW (jaw pain), EAR PAIN (ear pain), FATIGUE ("knocked out from tiredness") and FATIGUE (tiredness) had not resolved.            Other concomitant drugs include Actv, Omega 3s.
The patient received a third dose of Moderna 7 months from her second dose. However, she did not meet the eligibility requirements to receive an additional dose. Patient does not have report any adverse effects.
Dose #1 was administered at the correct dose.  Dose #2 was administered at the incorrect dose (the vaccine for 5-11 yo was given to a 12 year old child).
1st shot hurt for a couple of days/some soreness with the 1st dose of the Moderna vaccine which lasted for a couple of days; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (1st shot hurt for a couple of days/some soreness with the 1st dose of the Moderna vaccine which lasted for a couple of days) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 021C21A) for COVID-19 vaccination.     The patient neither had COVID positive test nor COVID diagnosis. The patient did not receive other vaccines which were given within 1 month prior to Moderna COVID-19 vaccine.  Concurrent medical conditions included Drug allergy (most narcotic medications) and Depression. Concomitant products included ESCITALOPRAM for Depression.    On 26-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 26-Aug-2021, the patient experienced PAIN (1st shot hurt for a couple of days/some soreness with the 1st dose of the Moderna vaccine which lasted for a couple of days). On 28-Aug-2021, PAIN (1st shot hurt for a couple of days/some soreness with the 1st dose of the Moderna vaccine which lasted for a couple of days) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       No treatment information was provided by the reporter.   This case was linked to MOD-2022-542579 (Patient Link).
Transient lightheadedness with brief syncope.   Subsequent NV controlled with position of comfort.  Patient had not eaten anything today and had only coffee so far.    Pt was given fruit, muffin and water and was monitored for an additional 45 minutes with continued improvement and no other symptoms.
Child was seen at the clinic  For COVID-19  Bi-Valent Pfizer third dose  Vaccine on 06/23/2023 Pfizer Bivalent 12 years and older ( diluted with  1.3 ml   0.9% Sodium Chloride ) 0.2 ML Administered at  Left Deltoid Instead of Pfizer Bivalent  5-11 years ,  which was discovered  during the documentation process . Dr. and Department of health  were  notified.  Provider discussed the Vaccine Issue with the mother  and another appointment made  in 4 weeks.. Child   was observed in the room more than 30 minutes and left the Clinic in stable condition.
Case was fully vaccinated for Covid by March 2021, then was hospitalized for it in November 2021. Plan: Symptoms 2 weeks prior to hospitalization/test. Treated with remdesivir and dexamethasone Procalcitonin TX w/ ceftriaxone.
The left arm has been feeling tired with activities, in particular with playing the violin. If she tries to push herself to use the arm her arm, then feels sore and eventually starts to hurt. If she continues to use the arm after this point her arm can feel like it is giving out. Once she gets to that point it takes a while for it to feel better again. This was worse in the first couple of weeks after the vaccine, then improved slightly but has continued to now - 5 weeks postvaccine. She is being sent to physical therapy for an evaluation and treatment.